Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TYMS | P04818 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.35 |
| ▸ | CDC7 | O00311 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 2/20 | 0.33 |
| ▸ | GAK | O14976 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL97819 | 0.77 | KMT2A (0.38) | MEN1KMT2AADRA2AADRA2CGLA | |
| SCHEMBL622637 | 0.77 | CDK5 (0.47) | GLAGAACDC7GAKTGFBR1 | |
| Methane SCHEMBL28258537 | 0.76 | CDK5 (0.46) | GLAGAACDC7GAKTGFBR1 | |
| SCHEMBL738379 | 0.75 | NPC1 (0.57) | MEN1KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL740305 | 0.75 | ALDH1A1 (0.53) | MEN1KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL28792535 | 0.75 | ALDH1A1 (0.39) | HDAC8MEN1KMT2AGABRA1GABRG2 | |
| SCHEMBL6156262 | 0.74 | KMT2A (0.33) | MEN1KMT2AADRA2AADRA2CGLA | |
| Hydrochloric Acid SCHEMBL21436092 | 0.74 | NPC1 (0.55) | MEN1KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL4277785 | 0.74 | MELK (0.50) | MEN1KMT2AGAAGABRA1GABRG2 | |
| SCHEMBL23999965 | 0.72 | EGFR (0.46) | HDAC8MAP3K14MEN1KMT2ATYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4634169-A1 | 3-FLUORO-4-HYDROXYBENZMIDE-CONTAINING INHIBITORS AND/OR DEGRADERS AND USES THEREOF | Pfizer Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-4598908-A1 | HSD17B13 INHIBITORS AND/OR DEGRADERS | Pfizer Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | PFIZER INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | PFIZER INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240228506-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240228506-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240228506-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-07-11 | — | — | US | disclosed |
| WO-2024127297-A1 | 3-FLUORO-4-HYDROXYBENZMIDE-CONTAINING INHIBITORS AND/OR DEGRADERS AND USES THEREOF | PFIZER INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024127297-A1 | 3-FLUORO-4-HYDROXYBENZMIDE-CONTAINING INHIBITORS AND/OR DEGRADERS AND USES THEREOF | PFIZER INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| CN-112292386-B | Tetrahydropyrane-based thiodisaccharide mimetics as galectin-3 inhibitors | 百时美施贵宝公司 | 2024-06-11 | — | — | CN | disclosed |
| EP-2935262-A1 | NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS (GPR84 ANTAGONISTS) | Galapagos NV (BE) | 2015-10-28 | — | — | EP | disclosed |
| CN-104870445-A | NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS (GPR84 ANTAGONISTS) | GALAPAGOS NV | 2015-08-26 | — | — | CN | disclosed |
| WO-2014095798-A1 | NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS (GPR84 ANTAGONISTS) | GALAPAGOS NV (BE) | 2014-06-26 | — | — | WO | disclosed |
| EP-1847545-B1 | SUBSTITUTED ETHYNYL GOLD-NITROGENATED HETEROCYCLIC CARBENE COMPLEX AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | UBE INDUSTRIES (JP) | 2013-03-06 | — | — | EP | disclosed |
| CN-101111499-B | Substituted ethynyl gold-nitrogen-containing heterocyclic carbene complex and organic electroluminescent device using the same | UBE INDUSTRIES | 2012-05-23 | — | — | CN | disclosed |
| US-8137821-B2 | Substituted ethynyl gold-nitrogen containing heterocyclic carbene complex and organic electroluminescent device using the same | UBE INDUSTRIES, LTD. (JP) | 2012-03-20 | — | — | US | disclosed |
| US-20090091243-A1 | Substituted Ethynyl Gold-Nitrogen Containing Heterocyclic Carbene Complex and Organic Electroluminescent Device Using the Same | UBE INDUSTRIES, LTD. (JP) | 2009-04-09 | — | — | US | disclosed |
| CN-101111499-A | Substituted ethynyl gold-nitrogenated heterocyclic carbene complex and organic electroluminescent device using same | UBE INDUSTRIES (JP) | 2008-01-23 | — | — | CN | disclosed |
| EP-1847545-A1 | SUBSTITUTED ETHYNYL GOLD-NITROGENATED HETEROCYCLIC CARBENE COMPLEX AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | Ube Industries, Ltd. (JP) | 2007-10-24 | — | — | EP | disclosed |
| WO-2002055077-A1 | USE OF IMIDAZOLYL CYCLIC ACETAL DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF DISEASES MEDIATED BY THE ALK5 RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | HSD17B13, HSD17B3, HSD17B1 | HDAC8 278/4885MAP3K14 2384/4885MEN1 4182/4885 |
| US-20240228506-A1 | RIPK1 INHIBITORS AND METHODS OF USE | RIPK1, RIPK2, RIPK3 | HDAC8 833/4885MAP3K14 44/4885MEN1 2685/4885 |
| US-20090091243-A1 | Substituted Ethynyl Gold-Nitrogen Containing Heterocyclic Carbene Complex and Organic Electroluminescent Device Using the Same | ACSL3, ATXN2L, ACSL1 | HDAC8 3646/4885MAP3K14 2401/4885MEN1 3642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.